Orexigen Shares Popped: What You Need to Know

Don't let it get away!

Keep track of the stocks that matter to you.

Help yourself with the Fool's FREE and easy new watchlist service today.

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of drug developer Orexigen Therapeutics (Nasdaq: OREX  ) spiked today, gaining as much as 22% in intraday trading on heavy volume.

So what: Orexigen issued a press release today saying that it will announce a regulatory update Friday. The announcement will be before the markets open and will be followed by a conference call.

Now what: Above is the entirety of the news out today on Orexigen -- and yet, shares are surging. Why? Obviously investors are guessing that the company will have something positive to say about its diet pill Contrave, which was denied approval by the Food and Drug Administration earlier this year. The future of Contrave is intriguing -- unlike drugs from competitors VIVUS (Nasdaq: VVUS  ) and Arena Pharmaceuticals (Nasdaq: ARNA  ) , it got a strong nod from a Food and Drug Administration advisory panel -- so it's not too surprising that optimistic investors are still hanging around.

However, the lack of substantive news today means that investors are just assuming what Friday's announcement will bring. And as the saying goes, assuming makes an ... well, you know how it goes.

Want to keep up to date on these stocks?

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

Fool contributor Matt Koppenheffer does not have a financial interest in any of the companies mentioned. You can check out what Matt is keeping an eye on by visiting his CAPS portfolio, or you can follow Matt on Twitter @KoppTheFool or Facebook. The Fool’s disclosure policy prefers dividends over a sharp stick in the eye.

Read/Post Comments (1) | Recommend This Article (7)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On June 01, 2011, at 7:02 PM, Fuf123 wrote:

    What you need to know???

    And then you write crap like this?

    Totally useless article where nothing was said

Add your comment.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1502016, ~/Articles/ArticleHandler.aspx, 10/28/2016 6:15:08 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,161.19 -8.49 -0.05%
S&P 500 2,126.41 -6.63 -0.31%
NASD 5,190.10 -25.87 -0.50%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/28/2016 4:00 PM
OREX $2.75 Down -0.23 -7.72%
Orexigen Therapeut… CAPS Rating: *
ARNA $1.52 Down -0.04 -2.56%
Arena Pharmaceutic… CAPS Rating: ***
VVUS $1.10 Down -0.01 -0.90%
VIVUS CAPS Rating: **